Last reviewed · How we verify
Zaroxolyn (METOLAZONE)
Zaroxolyn (METOLAZONE) is a thiazide-like diuretic originally developed by UCB INC and currently owned by I3 Pharms. It targets carbonic anhydrase 7 and is a small molecule modality. Zaroxolyn was FDA approved in 1973 for the treatment of hypertensive disorder, peripheral edema due to chronic heart failure, pulmonary edema due to chronic heart failure, and renal disease with edema. The drug is off-patent with 13 generic manufacturers. Key safety considerations include its long half-life of 20.0 hours and moderate bioavailability of 65%.
At a glance
| Generic name | METOLAZONE |
|---|---|
| Sponsor | I3 Pharms |
| Drug class | Thiazide-like Diuretic [EPC] |
| Target | Carbonic anhydrase 7 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1973 |
Approved indications
- Hypertensive disorder
- Peripheral Edema due to Chronic Heart Failure
- Pulmonary Edema due to Chronic Heart Failure
- Renal Disease with Edema
Common side effects
- Hepatitis
- Intrahepatic cholestatic jaundice
- Pancreatitis
- Aplastic/hypoplastic anemia
- Agranulocytosis
- Leukopenia
- Thrombocytopenia
- Hypokalemia
- Hyponatremia
- Hyperuricemia
- Hypochloremia
- Hypochloremic alkalosis
Drug interactions
- paroxetine
Key clinical trials
- Add-on Diuretics in Acute Decompensated Heart Failure (PHASE2)
- Ertugliflozin in Chronic Heart Failure (PHASE2)
- Comparative Efficacy and Safety of Acetazolamide Versus Metolazone as an Adjunct to Standard Therapy in Patients With Acute Decompensated Heart Failure (NA)
- Efficacy of Diuretics in Kidney Disease (PHASE2)
- Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload (PHASE4)
- Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance (PHASE4)
- A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients (NA)
- Efficacy and Safety of Combination Diuretic Therapy in Patients With Acute Decompensated Heart Failure and Volume Overload (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zaroxolyn CI brief — competitive landscape report
- Zaroxolyn updates RSS · CI watch RSS
- I3 Pharms portfolio CI